Disconnect between COX-2 selective inhibition and cardiovascular risk in preclinical models.
Koshman YE, Bielinski AL, Bird BM, Green JR, Kowalkowski KL, Lai-Zhang J, Mahalingaiah PK, Sawicki JW, Talaty NN, Wilsey AS, Zafiratos MT, Van Vleet TR.
Koshman YE, et al. Among authors: talaty nn.
J Pharmacol Toxicol Methods. 2023 Mar-Apr;120:107251. doi: 10.1016/j.vascn.2023.107251. Epub 2023 Feb 13.
J Pharmacol Toxicol Methods. 2023.
PMID: 36792039
Clinical Trial.